Assessment of endothelial (dys)function in atrial fibrillation

Annals of Medicine

Volumn 41, Issue 8, 2009, Pages 576-590

  Krishnamoorthy, Suresh ^a   Lim, Sern H ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Endothelial dysfunction; Endothelial function; Endothelium; Flow mediated dilatation

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; N(G),N(G) DIMETHYLARGININE; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; WARFARIN;

BLOOD FLOW VELOCITY; CORONARY FLOW RESERVE; DOPPLER FLOWMETRY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; FUNCTIONAL ASSESSMENT; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; SYSTEMATIC REVIEW; THROMBOCYTE ADHESION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ANIMALS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 72949086264     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890903160726     Document Type: Review

References (127)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952
2. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546-554
3. Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost. 2008;100:11-13
4. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295-304.
5. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147:590-592
6. Watson T, Shantsila E, Lip GY. Mechanisms of thrombo-genesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373:155-166
7. Freestone B, Lip GY. The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie. 2008;28:207-212
8. Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol. 2008;127:135-137
9. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des. 2004;10:3591-3605
10. Castellot JJ, Addonizo ML, Rosenberg RD, Karnowsky MJ. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle growth. J Cell Biol. 1980;90:373-379
11. Rodomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-1058 (Pubitemid 17154788)
12. Kubes P, Suzukii M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;81:4651-4655
13. Bowie EJW, Solberg LA, Fass DN, Johnson CM, Knutson GJ, Stewart ML, et al. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J Clin Invest. 1986;78:26-30.
14. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol. 1995;90: 244-248
15. Pottinger BE, Read RC, Paleolog EG, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989;53:387-394
16. Blann AD. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol. 1991;50: 320-322
17. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155
18. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in non-valvular atrial fibrillation. Stroke. 1990;21:47-51.
19. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73:527-533
20. Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P, et al. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest. 2008;133:1203-1208
21. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke. 2003;34:413-417
22. Lane DA, Lip GY. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost. 2009;101:802-805
23. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000;31:828-833
24. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GY. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J. 2000;140:777-784
25. Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001;37:1436-1442
26. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003;111:137-142
27. Yamamoto K, Ikeda U, Seino Y, Mito H, Fujikawa H, Sekiguchi H, et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol. 1995;25:107-112
28. Li-Saw-Hee FL, Blann AD, Goldsmith I, Lip GY Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol. 1999;83: 1206-1209
29. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997;77:407-411
30. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107:3141-3145
31. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willbrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002;106:1962-1967
32. Jansson J, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991;66:351-355
33. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006;37:2294-2300
34. McDermott JR. Studies on the catabolism of Ng-methyl arginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylar-ginine in the rabbit. Biochem J. 1976;154:179-184
35. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037
36. Cooke JP. Asymmetrical dimethyl arginine: the uber marker? Circulation. 2004;109:1813-1818
37. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al. Asymmetrical dimethyl arginine, an endogenous nitric oxide synthase inhibitor in experimental hypertension. Hypertension. 1997;29:242-247
38. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with Type 2 diabetes mellitus. Am J Cardiol. 2001;88:1201-1203
39. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetrical dimethyl arginine (ADMA): a novel risk factor for endothelial function: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847
40. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99: 1141-1146 (Pubitemid 29120084)
41. Vallance P, Leone A, Claver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575
42. Cengel A, Sahinarslan A, Biberoglu G, Hasanoglu A, Tavil Y, Tulmac M, et al. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol. 2008;63:33-37
43. Xia W, Qu X, Yu Y, Zhang X, Feng W, Song Y Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol. 2008;31:1036-1040
44. Gearing AJ, Newman W Circulating adhesion molecules in disease. Immunol Today. 1993;14:506-512
45. Blann AS, Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanism and clinical implications. Blood Coagul Fibrinolysis. 1998;9:297-306.
46. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during athero-genesis. Science. 1991;251:788-791
47. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of soluble adhesion molecule E-selectin in essential hypertension. 1994;12:925-928
48. Blann AS, Waite MA. von Willebrand factor and solute E-selectin in hypertension. Influence of treatment value in predicting the progression of atherosclerosis. Coron Artery Dis. 1996;7:143-147
49. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336-1342
50. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 2001;37:2392-2397
51. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest. 2007;132:1253-1258
52. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544-1548
53. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res. 2008;122:85-90.
54. Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, et al. Circulating endothelial cells: Biomarker of vascular disease. Thromb Haemostat. 2005;93:228-235 (Pubitemid 40253726)
55. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood. 1999;93:2951-2958
56. Nadar SK, Lip GYH, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic strokes. Thromb Hae-most. 2005;94:707-712
57. Bull TM, Golpon H, Hebbel RP, Solovey A, Cool CD, Tuder RM, et al. Circulating endothelial cells in pulmonary hypertension. Thromb Haemost. 2003;90:698-703.
58. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anaemia. N Engl J Med. 1997;337:1584-1590
59. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet. 2003;361:206-210 (Pubitemid 36126220)
60. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004;110: 1794-1798
61. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, inter-leukin-6 and prognosis in patients with acute coronary syndromes. Blood. 2005;105:526-532
62. Freestone B, Lip GY, Chong AY, Nadar S, Lee KW, Blann AD. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Hae-most. 2005;94:702-706
63. Goette A, Jentsch-Ullrich K, Lendeckel U, Roken C, Agbaria M, Auricchio A, et al. Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide. Circulation. 2003;108:2446-2449
64. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol. 2006;26:2594-2604
65. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest. 2004;34:392-401.
66. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348-353
67. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001;104:2649-2652
68. Morel O, Hugel B, Jesel L, Lanza F, Douchet MP, Zupan M, Chauvin M, Cazenave JP, Freyssinet JM, Toti F. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Hae-most. 2004;91:345-353
69. Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multi infarct dementias. Thromb Res. 1993;72:295-304.
70. Ederhy S, Di Angelantonio E, Mallat Z, Hugel B, Janower S, Meuleman C, et al. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation. Am J Cardiol. 2007;100:989-994
71. Sadler JE. Thrombomodulin structure and function. Thromb Haemost. 1997;78:392-395
72. Esmon CT Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 1995;9:946-955
73. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest. 1985;76:2178-2181
74. Erdem Y, Usalan C, Haznedaroglu IC, Altun B, Arici M, Yasavul U, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens. 1999;12:1071-1076
75. Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y Clinical significance of measurements of urinary and serum thrombomodulin in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1996;33:99-104.
76. Blann AD, Admiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol. 1997;59:115-120
77. Constans J, Blann AD, Renard M, Guerin V, Conri C. Soluble thrombomodulin in hypercholesterolaemic patients. Lancet. 2000;355:145.
78. Gris JC, Branger B, Vecina F, al Sabadani B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int. 1994;46:807-813
79. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 1999;353:1729-1734
80. Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R, et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic non-rheumatic atrial fibrillation. Int J Cardiol. 2000;75:227-232
81. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265
82. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241
83. Matsuo S, Matsumoto T, Takashima H, Ohira N, Yamane T, Yasuda Y, et al. The relationship between flow-mediated brachial artery vasodilation and coronary vasomotor responses to bradykinin: comparison with those to acetylcholine. J Cardiovasc Pharmacol. 2004;44:164-170
84. Teragawa H, Ueda K, Matsuda K, Kimura M, Higashi Y, Oshima T, et al. Relationship between endothelial function in the coronary and brachial arteries. Clin Cardiol. 2005;8:460-466
85. Deng YB, Wang XF, Le GR, Zhang QP, Li CL, Zhang YG. Evaluation of endothelial function in hypertensive elderly patients with high-resolution ultrasonography. Clin Cardiol. 1999;22:705-710
86. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium dependent and independent dilatation of forearm resistance arteries in men with diet treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Colch). 1996;91:567-573
87. Takase B, Uehata A, Akima T Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535-1539
88. Stroes ES, Koomans HA, De Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemia patients off and on lipid-lowering medication. Lancet. 1995;346:467-471
89. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Gerogga-kapoulos D, Robinson J, Deanfield JE. Ageing is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24:471-476
90. van der Heijden-Spek JJ, Staessen JA, Fagard RH, Hoeks AP, Boudier HA, van Bortel LM. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study. Hypertension. 2000;35: 637-642
91. Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Celermajer DS. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann Intern Med. 1999;130:578-581
92. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131
93. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, et al. Effect of treatment on flow-dependent vasodilatation of the brachial artery in essential hypertension. Hypertension. 1999;33:575-580
94. Skalidis EI, Zacharis EA, Tsetis DK, Pagonidis K, Chlouverakis G, Yarmenitis S, et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol. 2007;99:1258-1262
95. Guazzi M, Belletti S, Lenatti L, Bianco E, Guazzi MD. Effects of cardioversion of atrial fibrillation on endothelial function in hypertension or diabetes. Eur J Clin Invest. 2007;37:26-34.
96. Collins P. Coronary flow reserve. Br Heart J. 1993;69:279-281
97. Gullu H, Erdogan D, Caliskan M, Tok D, Yildirim E, Ulus T, et al. Interrelationship between noninvasive predictors of atherosclerosis: transthoracic coronary flow reserve, flow-mediated dilation, carotid intima-media thickness, aortic stiffness, aortic distensibility, elastic modulus, and brachial artery diameter. Echocardiography. 2006;3:35-42
98. Pellegrino T, Storto G, Filardi PP, Sorrentino AR, Silvestro A, Petretta M, et al. Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. J Nucl Med. 2005;46:1997-2002. (Pubitemid 46657445)
99. Marcus M, Wright C, Doty D, Eastham C, Laughlin D, Krumm P, et al. Measurements of coronary velocity and reactive hyperemia in the coronary circulation of humans. Circ Res. 1981;49:877-891
100. Felder L, Vassalli G, Vassalli F, Jiang Z, Grimm J, Krayenbuehl HP, et al. Clinical significance of coronary flow reserve: effect of papaverine and exercise. Coron Artery Dis. 1994;5:347-358
101. Christensen CW, Rosen LB, Gal RA, Hasseb M, Lassar TA, Port SC. Coronary vasodilator reserve. Comparison of the effects of papaverine and adenosine on coronary flow, ventricular function and myocardial metabolism. Circulation. 1991;83:294-303.
102. Rossen JD, Quillen JE, Lopez AG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol. 1991;18:485-491
103. Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG. Understanding the coronary circulation through studies at the microvascular level. Circulation. 1990;82:1-7.
104. Olsen MH, Wachtell K, Meyer C, Hove JD, Palmieri V, Dige-Petersen H, et al. Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy. J Hum Hypertens. 2004;18:445-452
105. Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation. 1995;91:635-640
106. Selke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic patients. Circulation. 1990;81:1586-1593
107. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stage of coronary atherosclerosis. Circulation. 1991;83:391-401
108. Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercho-lesterolemic patients without overt coronary stenosis. Circulation. 1996;94:3232-3238
109. Tok D, Gullu H, Erdogan D, Topcu S, Ciftci O, Yildirim I, et al. Impaired coronary flow reserve in hemodialysis patients: a transthoracic Doppler echocardiographic study. Nephron Clin Pract. 2005;101:c200-6.
110. Ashikaga T, Nishizaki M, Fujii H, Niki S, Maeda S, Yamawake N, et al. Examination of the microcirculation damage in smokers versus nonsmokers with vasospastic angina pectoris. Am J Cardiol. 2007;100:962-.
111. Sulli A, Ghio M, Bezante GP, Deferrari L, Craviotto C, Sebastiani V, et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford). 2004;43:505-509
112. Hirata K, Kadirvelu A, Kinjo M, Sciacca R, Sugioka K, Otsuka R, et al. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56:1904-1909
113. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906
114. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954
115. kalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol. 2008;51:2053-2057
116. Range FT, Schafers M, Acil T, Schafers KP, Kies P, Paul M, et al. Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur Heart J. 2007;28:2223-2230
117. Takahashi N, Ishibashi Y, Shimada T, Sakane T, Ohata S, Sugamori T, et al. Atrial fibrillation impairs endothelial function of forearm vessels in humans. J Card Fail. 2001;7:45-54.
118. Takahashi N, Ishibashi Y, Shimada T, Sakane T, Ohata S, Sugamori T, et al. Impaired exercise-induced vasodilatation in chronic atrial fibrillation*role of endothelium-derived nitric oxide. Circ J. 2002;66:583-588
119. Freestone B, Chong AY, Blann AD, Lip GY The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction. Thromb Res. 2006;118:479-485
120. Freestone B, Chong AY, Lim HS, Blann A, Lip GY. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med. 2005;37:365-372
121. Lip GY, Pearce LA, Chin BS, Conway DS, Hart RG. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvular atrial fibrillation. Heart. 2005;91:759-763
122. Marin F, Roldan V, Climent VE, Ibanez A, Garcia A, Marco P, et al. Plasma von Willebrand factor, soluble thrombomodulin and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart. 2004; 90:1162-1166
123. Goette A, Weber M, Lendenckel U, Welte T, Lutze G, Klein HU. Effect of physical exercise on platelet activity and the von Willebrand factor in patients with persistent atrial fibrillation. J Interv Card Electrophysiol. 2004; 10:139-146
124. Roldan V, Marin F, Blann AD, Garcia A, Marco P, Sogrob F, Lip GY. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J. 2003;24:1373-1380
125. Nikitovic D, Zacharis EA, Manios EG, Malliaraki NE, Kanoupakis EM, Sfiridaki KI, et al. Plasma levels of nitrites/nitrates in patients with chronic atrial fibrillation are increased after electrical restoration of sinus rhythm. J Interv Card Electrophysiol. 2002;7:171-176
126. Feng D, D'Agostino RB, Silbershatz H, Lipinska I, Massaro J, Levy D, et al. Hemostatic state ad atrial fibrillation (the Framingham Offspring Study). Am J Cardiol. 2001;87: 168-171
127. Li Saw Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001;22:1741-1747